The stock market lost ground on Thursday, but declines in the major benchmarks were relatively modest as low levels of volatility continued to prevail. The Dow had been down as much as 145 points earlier in the day as investors weighed the possibility that the controversial firing of FBI Director James Comey could set back the Trump administration’s domestic agenda for tax cuts, health reform, and immigration. In addition, bad news among several major retailers weighed on market sentiment.
But some stocks managed to buck the trend and give investors more upbeat outlooks for their prospects. SandRidge Energy (NYSE: SD), MBIA (NYSE:MBI), and LivePerson (NASDAQ:LPSN) were among the best performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.
SandRidge gives investors a good report
Shares of SandRidge climbed 10% after the company reported its first-quarter financial results. The energy company said that it earned a profit of $50.8 million, which worked out to $1.90 per share, reversing a loss in the year-ago period prior to SandRidge’s emergence from bankruptcy in late 2016. SandRidge produced 4 million barrels of oil equivalent during the quarter, half of which was dry natural gas and the remainder split between crude oil and natural gas liquids. Lifting costs rose slightly during the quarter, but SandRidge continued to benefit from efforts to improve operating efficiency. In total, the energy company expects to produce between 14 million and 14.7 million barrels of oil equivalent during 2017, and it’s working hard to minimize discounts compared to West Texas Intermediate crude and Henry Hub spot natural gas prices and reap the most in profit that it can.
stock market sectors: Orocobre Limited (OROCF)
- [By SEEKINGALPHA.COM]
The question now is more about speed of EV implementation. On the supply side, it has been great to see LAC, Pilbara Minerals (OTCPK:PILBF) and Altura Mining (OTCPK:ALTAF) get funding, but the continued issues with Albemarle’s (NYSE:ALB) LaNegra II expansion and Orocobre (OTCPK:OROCF) ramping up to Phase 1 capacity of 17,500 tonnes/year of lithium carbonate are further evidence that lithium projects take time and have considerable execution risk.
- [By SEEKINGALPHA.COM]
The other producing lithium miners, and soon to be producers. I have discussed these previously in detail here, here and here. Needless to say, the top 3 producers are non-pure plays (SQM (NYSE:SQM), Albemarle (NYSE:ALB), and FMC Corp. (NYSE:FMC)). The top pure play currently producing miners are Orocobre (ASX:ORE) (OTCPK:OROCF), Tianqi Lithium (SHE:002466), Jiangxi Ganfeng Lithium, Galaxy Resources, Mineral Resources [ASX:MIN] (OTC:MALRF), and Neometals [ASX:NMT] (OTC:RRSSF). The near-term producers include Altura Mining [ASX:AJM] (OTCPK:ALTAF), Pilbara Minerals (ASX:PLS) (OTC:PILBF), Kidman Resources (ASX:KDR), Critical Elements, Nemaska Lithium (OTCQX:NMKEF) [TSX:NMX], Lithium Americas (OTCQX:LACDF) [TSX:LAC], Lithium X (OTCQX:LIXXF) (TSXV:LIX), Neo Lithium, and Bacanora Minerals (OTC:BCRMF) [TSXV:BCN], Advantage Lithium (OTCQB:AVLIF) [AAL], European Metals (OTCPK:MNTCF, ASX:EMH, AIM:EMH) and Pure Energy (OTCQB:PEMIF) [PE].
stock market sectors: IDT Corporation(IDT)
- [By Lisa Levin]
IDT Corporation (NYSE: IDT) was down, falling around 15 percent to $15.88 following Q2 results. IDT reported fiscal second-quarter earnings of $875,000.
stock market sectors: GlaxoSmithKline PLC(GSK)
- [By WWW.THESTREET.COM]
Up first on our list of potentially toxic trades is $98 billion healthcare stock GlaxoSmithKline plc (GSK) . GSK has actually been an attractive name to own lately. Shares are up about 10.6% since bottoming back in December, besting the S&P over that timeframe. But if you own GlaxoSmithKline, now’s the time to start thinking about taking some of those recent gains off the table — shares are looking “toppy” this spring.
- [By WWW.MONEYSHOW.COM]
Donald Trump understands how regulation harms both businesses and consumers, discouraging innovation and raising costs. In a recent news conference, he pledged to “cut regulations by 75%, maybe more.” This is good news indeed for drug companies like GlaxoSmithKline (GSK).
- [By Todd Campbell]
Also, like in hepatitis C, competitors are attempting to win away market share. For example,ViiV Healthcare, a joint venture spearheaded by GlaxoSmithKline(NYSE:GSK), is actively pursuing new HIV therapies that could make it more difficult for Gilead Sciences to maintain its market share dominance. In December, ViiV announced that a single tablet, two-drug combination that includes Johnson & Johnson’s Edurant met its primary endpoint in phase 3 studies. A filing for FDA approval is slated for this year.
- [By Keith Speights]
There are several choices for investing in HIV drug stocks. Three of the best options for long-term investors are Gilead Sciences (NASDAQ:GILD), GlaxoSmithKline (NYSE:GSK), and Merck (NYSE:MRK). Here’s why these HIV drug stocks could be solid picks in 2017.
stock market sectors: Graco Inc.(GGG)
- [By Joel Elconin]
At this time, the only relevant news to the Gold market and Gold stocks was the halt of Graco Inc. (NYSE: GGG), which was down $0.80 at $84.64 and just reopened at $82.20.
- [By Lisa Levin]
In trading on Thursday, industrials shares fell by 0.83 percent. Meanwhile, top losers in the sector included Graco Inc. (NYSE: GGG), down 9 percent, and Southwest Airlines Co (NYSE: LUV), down 11 percent.